RETN and obesity disorder: Plasminogen activator inhibitor-1 (PAI-1) showed an increase (p < 0.001), C3, an immune marker was significantly decreased (p < 0.01) and resistin, an adipokine involved in obesity and Type-2 diabetes, was also significantly decreased (p < 0.05).